Context Therapeutics Inc. 8-K

What Happened
Context Therapeutics Inc. (CNTX) filed a Form 8-K (dated June 26, 2026) disclosing that at its Annual Meeting of Stockholders on June 24, 2026 shareholders approved an amendment to the company’s Amended and Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 shares to 300,000,000 shares. The Certificate of Amendment was filed with the Delaware Secretary of State on June 24, 2026.

Key Details

• Record date: April 27, 2026. Shares outstanding and entitled to vote: 91,879,177. Shares present or by proxy: 72,830,990 (≈79.27%), constituting a quorum.
• Amendment vote (Proposal 3): For 71,752,165; Against 1,050,867; Abstentions 27,958 — amendment approved.
• Directors elected (Proposal 1): Seven nominees elected to serve until 2027 — Dr. Philip Kantoff, Martin Lehr, Andy Pasternak, Dr. Karen Smith, Jennifer Evans Stacey, Dr. Luke Walker, and Linda West. (Notably, Jennifer Evans Stacey received ~2,020,712 withhold votes.)
• Auditor ratified (Proposal 2): CohnReznick LLP ratified as independent registered public accounting firm (72,762,152 For).

Why It Matters
Increasing the number of authorized common shares gives the company flexibility to issue additional shares in the future for purposes such as equity financings, employee compensation plans, acquisitions, or other corporate needs. This is a charter-level change approved by shareholders; it does not by itself issue new shares or change current ownership percentages, but it permits the company to do so later if the board chooses. Investors should watch for any subsequent filings (e.g., equity offerings, registration statements, or stock-based compensation disclosures) that would actually issue shares and could dilute existing holdings.